Pibarot, PhilippeSimonato, MatheusBarbanti, MarcoLinke, AxelKornowski, RanRudolph, TanjaSpence, MarkMoat, NeilAldea, GabrielMennuni, MarcoIadanza, AlessandroAmrane, HafidGaia, DiegoKim, Won-KeunNapodano, MassimoBaumbach, HardyFinkelstein, ArielKobayashi, JunjiroBrecker, StephenDon, CreightonCerillo, AlfredoUnbehaun, AxelAttias, DavidNejjari, MohammedJones, NoahFiorina, ClaudiaTchetche, DidierPhilippart, RaphaelSpargias, KonstantinosHernandez, Jose-MariaLatib, AzeemDvir, Danny2023-01-252023-01-252018http://hdl.handle.net/10668/12027The aim of this study was to determine whether the association of small label size of the surgical valve with increased mortality after transcatheter valve-in-valve (ViV) implantation is, at least in part, related to pre-existing prosthesis-patient mismatch (PPM) (i.e., a bioprosthesis that is too small in relation to body size). Transcatheter ViV implantation is an alternative for the treatment of patients with degenerated bioprostheses. Small label size of the surgical valve has been associated with increased mortality after ViV implantation. Data from 1,168 patients included in the VIVID (Valve-in-Valve International Data) registry were analyzed. Pre-existing PPM of the surgical valve was determined using a reference value of effective orifice area for each given model and size of implanted prosthetic valve indexed for body surface area. Severe PPM was defined according to the criteria proposed by the Valve Academic Research Consortium 2: indexed effective orifice area  Among the 1,168 patients included in the registry, 89 (7.6%) had pre-existing severe PPM. Patients with severe PPM had higher 30-day (10.3%, p = 0.01) and 1-year (unadjusted: 28.6%, p  Pre-existing PPM of the failed surgical valve is strongly and independently associated with increased risk for mortality following ViV implantation.enprosthesis-patient-mismatchtranscatheter aortic valve replacementvalve-in-valveAgedAged, 80 and overAortic ValveAortic Valve InsufficiencyAortic Valve StenosisBioprosthesisFemaleHeart Valve ProsthesisHeart Valve Prosthesis ImplantationHumansMaleProsthesis DesignProsthesis FailureRegistriesRisk AssessmentRisk FactorsTime FactorsTranscatheter Aortic Valve ReplacementTreatment Outcomeresearch article29348008open access10.1016/j.jcin.2017.08.0391876-7605https://doi.org/10.1016/j.jcin.2017.08.039